TP53 and neoplasm: USP7 inhibition in the CT‐26 tumour model in vivo was verified by monitoring USP7 target engagement (Figure S6D) as well as by monitoring induction of the well‐characterized biomarker of p53 pathway activation, GDF‐1535 (Figure S6E).